Sjögren病の病因と治療に関する研究 第2編 Sjögren病単独例に対する副腎皮質ホルモン剤の効果

The effect of prednisolone (PSL) on clinical symptoms and laboratory parameters was studied in nineteen patients with Sjögren's syndrome (SjS) without associated diseases (SjS alone). The mean initial dose of PSL was 11.7±13.0 mg/day (M±SD), and the mean maintenance dose was 6.1±3.9 mg/day. The mean duration of the treatment was 25.2±14.1 months. Fever, polyarthralgia, elevated erythrocyte sedimentation rate, and hypergamma-globlinemia were improved by the PSL treatment. However, no effect of PSL on the ocular and oral sicca symptoms including parotid enlargements, function of the exocrine glands and sialographical findings of parotid glands was observed. Neither Raynaud's phenomenon nor various autoantibodies detected in patients' sera was affected by this treatment.